Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches

NCT01841801 | Completed DMC

• 1 other identifier: 2012007
• Study Type: interventional
• Target: 157
• Locations: 1 country
• Sites: 1

Brief Summary

To assess the safety and tolerability for the extended wear of an experimental air-activated self adhesive patch.

Conditions

Effects of Heat; Tolerability; Adhesiveness; Dermal Irritation

Outcome Measures

Primary Outcomes (1)

• Irritation Evaluation

  A trained skin grader will apply a predetermined scale to the observed skin reactions in the test areas under light supplied by a 100-watt incandescent blue bulb.

  7 days - 8 hours each day

Secondary Outcomes (1)

• Adhesion Evaluation

  after 8 hours

Other Outcomes (1)

• Heat Intensity

  8 hours

Study Arms (3)

Marketed Thermal Adhesive Patch

ACTIVE COMPARATOR

Group of subjects wearing comparative predicate device for 8 hours daily for 7 days.

Device: Marketed Thermal Adhesive Patch

Thermal Adhesive Patch

EXPERIMENTAL

Group of subjects wearing the experimental patch for 8 hours daily for 7 days.

Device: Thermal Adhesive Patch

Placebo Patch

PLACEBO COMPARATOR

Group of subjects wearing the placebo patch for 8 hours daily for 7 days.

Device: Placebo Patch

Interventions

Thermal Adhesive Patch DEVICE

Thermal Adhesive Patch

Marketed Thermal Adhesive Patch DEVICE

Also known as: ThermaCare Heat Wraps

Marketed Thermal Adhesive Patch

Placebo Patch DEVICE

Placebo Patch

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participants are 18 to 70 years of age;
• must be in general good health;
• must have absence of any visible disease that might be confused with a skin reaction to the test material;
• back region must be free from excessive hair, cuts, tatoos, or other aberrations;
• must understand and sign Informed Consent;
• must be considered dependable and able to follow directions;
• Participants assigned to the thermocouples must be willing to restrict their activity for the 8 hour patch wear time so that the thermocouples do not come loose;
• Participants assigned to the thermocouples must be willing to wear a pouch containing the thermostat and thermocouple wiring for the entire 8 hour period and to return all study supplies to the site at visit 15. If the items are not returned subject may be invoiced for the value of the unit;
• must be willing to not wear any topical products such as lotions, sunscreens, etc. in the test area while participating in the study;
• must agree to use an adequate means of birth control which include: abstinence, partner vasectomy, Intrauterine Device, hormonal implant devices/injections, regular use of birth control pills, birth control patches or condoms with a spermicidal agent;
• Participants are willing to come in each day with a CLEAN back;
• Participants who are 55 years of age and older, agree to supply a t-shirt to wear at visit two that can be marked on with a marker, and to use that t-shirt or supply others at the morning visits (visits 4, 6, 8, 10, 12, 14).

You may not qualify if:

• Participants with known skin sensitivity to adhesion products;
• Participants with any skin abnormality likely to be aggravated by the study material such as dermatological disease or infection, rash, atrophic, fragile, or abnormally dry skin, cuts or abrasions at the treatment site;
• Participants who are pregnant or nursing, oral interview only;
• Participants with diabetes or poor circulation;
• Participants unable to tolerate conditions of protocol;
• Participants viewed by the investigator as not being suitable for the study;
• Participants who have had active skin cancer including basal cell carcinoma, or other cancer within one year;
• Participants who are currently participating in another clinical trial;
• Participants who routinely use anti-inflammatory medications (within 5 days of study start (81mg aspirin is okay)) or immunosuppressive or antihistamine medications within 3 weeks prior to study start (steroid nose/eye drops are ok);
• Participants who currently use allergy injections;
• Participants with history of severe asthma;
• Participants with active or uncontrolled immunologic disorders i.e. AIDS, HIV positive, systemic lupus erythematosus, rheumatoid arthritis;
• Participants with uncontrolled thyroid disease;
• Participants who have any clinically significant chronic illness which could place the subject at increased risk during participation or result in inappropriate dermal response during the study;
• Participants who have used topical medications at the test sites within the past 14 days;

Sponsors & Collaborators

• Chattem, Inc.: lead

Study Sites (1)

Radiant Research, Inc

Pinellas Park, Florida, 33781, United States

Location

Study Officials

• Daniel J Hogan, MD

  Radiant Research

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: OTHER
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 23, 2013
• First Posted: April 29, 2013
• Study Start: October 1, 2012
• Primary Completion: December 1, 2012
• Study Completion: December 1, 2012
• Last Updated: March 17, 2017

Record last verified: 2013-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)